TrialDiabetes, obesity & metabolism2018

Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials.

Mark Warren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.